-
Dec 12, 2012
-
Contract manufacturing: Granules bets on partner OmniChem’s strength
The Rs 654-crore drug-maker Granules India is not worried at being a late entrant in the contract research and manufacturing (CRAM) business. Through its equally-partnered venture with Ajinomoto OmniChem, Granules is set to work with innovative companies on products that are still to come off patent-protection. “We are not a late entrant, since the joint-venture partner has a history in CRAMS,” says Granules Chief Executive Bhaskar Krishna Arumugam. “If we were doing it all from scratch, it would have been too much of a risk,” he says. In fact, it is a good way to enter, since, the partner company has its customer relationships, marketing team and credibility, he adds.
Source -
http://www.thehindubusinessline.com
|